Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

146 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Switching to Low Neurotoxic Antiretrovirals to Improve Neurocognition Among People Living With HIV-1-Associated Neurocognitive Disorder: The MARAND-X Randomized Clinical Trial.
Lazzaro A, Vai D, Barco A, Stroffolini G, Pirriatore V, Guastamacchia G, Nigra M, Ghisetti V, Tettoni MC, Noce G, Giaccone C, Trunfio M, Trentalange A, Bonora S, Di Perri G, Calcagno A. Lazzaro A, et al. Among authors: barco a. J Acquir Immune Defic Syndr. 2024 Oct 1;97(2):180-191. doi: 10.1097/QAI.0000000000003480. J Acquir Immune Defic Syndr. 2024. PMID: 39250652 Clinical Trial.
Correlations between cerebrospinal fluid biomarkers, neurocognitive tests, and resting-state electroencephalography (rsEEG) in patients with HIV-associated neurocognitive disorders.
Barco A, Orlando S, Stroffolini G, Pirriatore V, Lazzaro A, Vai D, Guastamacchia G, Noce G, Atzori C, Trunfio M, Bonora S, Di Perri G, Calcagno A. Barco A, et al. J Neurovirol. 2022 Apr;28(2):226-235. doi: 10.1007/s13365-021-01047-y. Epub 2022 Jan 19. J Neurovirol. 2022. PMID: 35044644
Changes in Cerebrospinal Fluid, Liver and Intima-media-thickness Biomarkers in Patients with HIV-associated Neurocognitive Disorders Randomized to a Less Neurotoxic Treatment Regimen.
Stroffolini G, Lazzaro A, Barco A, Pirriatore V, Vai D, Giaccone C, Nigra M, Atzori C, Trunfio M, Bonora S, Di Perri G G, Calcagno A. Stroffolini G, et al. Among authors: barco a. J Neuroimmune Pharmacol. 2023 Dec;18(4):551-562. doi: 10.1007/s11481-023-10086-7. Epub 2023 Oct 31. J Neuroimmune Pharmacol. 2023. PMID: 37906406 Free PMC article. Clinical Trial.
Cerebral white matter Hyperintensities in HIV-positive patients.
Trentalange A, Prochet A, Imperiale D, Cusato J, Tettoni M, Nunnari G, Barco A, Bonora S, Di Perri G, Calcagno A. Trentalange A, et al. Among authors: barco a. Brain Imaging Behav. 2020 Feb;14(1):10-18. doi: 10.1007/s11682-018-9966-1. Brain Imaging Behav. 2020. PMID: 30238207
Rifampicin and Isoniazid Maximal Concentrations are Below Efficacy-associated Thresholds in the Majority of Patients: Time to Increase the Doses?
Trentalange A, Borgogno E, Motta I, Antonucci M, Pirriatore V, Costa C, Rossi G, Barco A, De Nicolò A, Piccioni P, D'Avolio A, Bonora S, Di Perri G, Calcagno A. Trentalange A, et al. Among authors: barco a. Int J Antimicrob Agents. 2021 Mar;57(3):106297. doi: 10.1016/j.ijantimicag.2021.106297. Epub 2021 Feb 1. Int J Antimicrob Agents. 2021. PMID: 33539932
146 results